‘IME Funding Info’ Category

GlaxoSmithKline’s Marketing Payments Announcement

Posted on: January 9, 2014 Permalink: Bookmark Discussion: No Comments Tags: , ,

Today we are going to be talking about GlaxoSmithKline’s recent announcement about payments to physicians for marketing purposes. In December of 2013, GSK decided to no longer to pay physicians directly to do one of three activities:

• Speak on their behalf
• Attend conferences on their behalf
• Directly market products on their behalf

Preparing for the Sunshine Act

Posted on: September 3, 2013 Permalink: Bookmark Discussion: No Comments No Tags

The Physician Payment Sunshine Act (PPSA) went into effect on August 1, 2013, and with it comes a few notable changes to CME. As part of our continued efforts in research and funder development within the CME industry, Global has taken the initiative in analyzing the complexities and ambiguity of the new guidelines.

Notes from the Pfizer Webinar Series

Posted on: August 16, 2010 Permalink: Bookmark Discussion: No Comments Tags: , ,

On Friday August 6, 2010, Don E. Moore, JR conducted a Pfizer webinar discussing outcomes assessments. For detailed notes and information from the Pfizer webinar, please see below.

Webcast: Pfizer First Friday Webinar Series: Outcomes Assessment
Date: Friday, August 6, 2010
Presenter: Don E. Moore, Jr., Ph.D

Novartis Oncology Webcast Highlights

Posted on: March 19, 2010 Permalink: Bookmark Discussion: No Comments No Tags

On March 15, 2010, Global participated in the Novartis Oncology Office of Grants & Education (OGE) and Oncology Affairs & Patient Advocacy (OA&PA) Informational Webcast. The highlights from the webinar are listed below:

Why More is Better: Seeking CME Funding from Multiple Sources

Posted on: October 13, 2009 Permalink: Bookmark Discussion: No Comments No Tags

In today’s playing field of certified medical education (CME) there is constant scrutiny from government and media stakeholders who believe that there is inherent bias in CME activities funded by pharmaceutical and medical device companies. In order to combat perceived bias many have suggested that commercial support of CME be eliminated, however others believe that commercial support is the only way to ensure high quality education is available to all physicians, nurses, pharmacists and other healthcare professionals.